Reuters logo
BRIEF-Cumberland Pharmaceuticals, Clinigen enter U.S. commercialization agreement for Totect
January 9, 2017 / 5:23 PM / 8 months ago

BRIEF-Cumberland Pharmaceuticals, Clinigen enter U.S. commercialization agreement for Totect

Jan 9 (Reuters) - Cumberland Pharmaceuticals Inc :

* Cumberland pharmaceuticals and Clinigen enter exclusive U.S. commercialization agreement for Totect

* Preparations are now underway for U.S. launch of Totect later this year

* Under terms Cumberland granted an exclusive U.S. license,will manage marketing, promotion, distribution of Totect in U.S.

* Clinigen SP to continue to commercialize Dexrazoxane products, Savene, Cardioxane, in Europe, other territories outside U.S. Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below